{"filings":[{"id":1138197,"accession_number":"0001725160-26-000052","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2026-06-18T20:03:10+00:00","items":["5.07"],"status":"ready","headline":"Zentalis shareholders elect two Class III directors, ratify auditor, approve say-on-pay at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["David Johnson and Jan Skvarka elected as Class III directors with 20.7M and 23.5M votes for, respectively.","Ratification of Ernst & Young as auditor for FY2026 passed with 49.3M votes for (99.7% of votes cast).","Advisory say-on-pay proposal approved with 21.9M for vs 10.9M against, excluding broker non-votes.","Approximately 69.5% of outstanding shares (49.5M) were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":695560,"accession_number":"0001725160-26-000049","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2026-05-27T20:07:11+00:00","items":["5.02"],"status":"ready","headline":"Zentalis appoints Shannon Campbell as Class I director, expanding board to 7 members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 6 to 7 directors; Campbell appointed as Class I director effective May 22, 2026.","Annual retainer of $45,000 for board service plus $7,500 for Compensation Committee membership.","Granted RSUs covering 114,200 shares on May 26, 2026, vesting one-third annually over three years.","After 6 months, eligible for annual equity grant of RSUs covering 0.08% of outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":584516,"accession_number":"0001725160-26-000045","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2026-05-21T21:29:34+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Zentalis reports 39% ORR, 7.3-month median PFS for azenosertib+paclitaxel in PROC at ASCO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1b MUIR trial: all-comer PROC (n=46), ORR 39.1%, CBR 58.7%, median DOR 5.6 mo, median PFS 7.3 mo.","At 250 mg intermittent dose (n=12): ORR 50.0%, median DOR 9.2 mo, median PFS 5.5 mo, manageable safety.","Cyclin E1-positive (ORR 41.4%) and -negative (ORR 35.7%) patients showed comparable activity.","Grade ≥3 TRAEs: neutropenia 30.4%, anemia 19.6%; one Grade 5 sepsis event previously reported.","Data supports combo expansion; core focus remains azenosertib monotherapy in Cyclin E1+ PROC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40406,"accession_number":"0001725160-26-000041","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2026-05-12T20:10:14+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Zentalis Q1 2026 cash $211.8M; selects pivotal azenosertib dose; DENALI readout by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities $211.8M as of March 31, 2026; provides runway into late 2027.","Selected 400mg QD 5:2 as pivotal dose for azenosertib monotherapy in Cyclin E1-positive PROC based on DENALI Part 2a interim.","DENALI Part 2 topline readout expected by year-end 2026; potential accelerated approval pathway.","ASPENOVA Phase 3 confirmatory trial in Cyclin E1-positive PROC initiated with first patient dosed.","Q1 total operating expenses $37.9M, down from $45.6M (includes $7.8M non-recurring restructuring in prior year)."],"consensus_eps_estimate":-0.4861,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95014,"accession_number":"0001725160-26-000033","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Zentalis first patient dosed in Phase 3 ASPENOVA trial for azenosertib in Cyclin E1+ PROC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 ASPENOVA compares azenosertib 400mg QD 5:2 to standard-of-care chemo in ~420 Cyclin E1+ platinum-resistant ovarian cancer patients.","Trial designed as confirmatory study to support full approval, with DENALI Part 2 topline expected by year-end 2026 for accelerated approval path.","400mg QD 5:2 dose selected based on DENALI Part 2a interim analysis showing differentiated response rate over 300mg with comparable safety.","Collaborators include GOG Foundation, ENGOT, and APGOT; trial identifier NCT07546500."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95013,"accession_number":"0001725160-26-000020","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zentalis presents preclinical azenosertib data in TNBC; real-world ovarian cancer outcomes shown","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Azenosertib + enfortumab vedotin induced 87.5% complete responses in ADC-resistant TNBC PDX model; 5 of 8 mice had no progression after treatment stop.","Median PFS not reached for azenosertib+EV vs. 22 days for EV alone (HR=0.14, p<0.0001) in TOP1i-ADC-resistant model.","Real-world data: Cyclin E1-positive ovarian cancer patients had shorter time to next treatment (13.2–14.9 months) vs. Cyclin E1-negative (19.5 months), p=0.002.","Azenosertib monotherapy showed 42–99% tumor growth inhibition across 12 TNBC xenograft models.","Data presented at AACR 2026; company plans to explore azenosertib combinations post-ADC in TNBC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95012,"accession_number":"0001725160-26-000017","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Zentalis selects 400mg QD 5:2 azenosertib monotherapy as pivotal dose for Cyclin E1-positive ovarian cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pre-specified interim analysis from DENALI Part 2a showed clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable safety profiles.","New DENALI Part 2c cohort to include ~40 patients previously treated with taxane-containing regimen for PROC, enrollment expected Q2 2026.","Company expects to complete enrollment in all DENALI Part 2 cohorts and provide topline readout by year-end 2026.","Azenosertib therapeutic profile supports advancement into confirmatory ASPENOVA Phase 3 trial and pre-commercial activities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107784,"accession_number":"0001725160-26-000010","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zentalis reports FY2025 results; cash $245.9M, DENALI Part 2 topline due year-end 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $245.9M as of Dec 31, 2025; projected runway into late 2027.","R&D expenses $107.3M (down 36% YoY); G&A expenses $37.7M (down 57% YoY).","DENALI Part 2a enrollment completed; monotherapy dose confirmation expected 1H 2026.","DENALI Part 2 topline readout on track for year-end 2026; potential to support accelerated approval.","ASPENOVA Phase 3 confirmatory trial (azenosertib vs chemo in Cyclin E1+ PROC) to initiate 1H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107783,"accession_number":"0001725160-26-000003","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Zentalis updates azenosertib program; DENALI Part 2 topline readout expected by year-end 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed enrollment in DENALI Part 2a, supporting registration-intended development of azenosertib.","Aligned with FDA on confirmatory ASPENOVA Phase 3 trial design for Cyclin E1-positive PROC.","Cash, equivalents and securities of $280.7M as of Sep 30, 2025; runway into late 2027.","2026 milestones: Part 2a dose confirmation H1, ASPENOVA initiation H1, Part 2 topline by YE.","DENALI Part 2, if successful, could support accelerated approval for azenosertib in PROC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124172,"accession_number":"0001725160-25-000164","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["5.01","8.01"],"status":"ready","headline":"Zentalis repurchases 7.5M shares from Matrix at $1.33 each; director resigns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Repurchased 7,500,000 shares from Matrix Capital Master Fund at $1.33/share, a 5% discount to the Dec 12 close of $1.40.","Repurchase closed on December 15, 2025; funded by existing cash, with no material impact on projected cash runway into late 2027.","Director Karan Takhar (Matrix Capital) resigned immediately, reducing board size from 7 to 6; resignation not due to any disagreement.","Matrix's sale is part of its previously announced 2024 plan to wind down its family of funds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124171,"accession_number":"0001725160-25-000159","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Zentalis Q3 cash $280.7M, cuts R&D spend 37% YoY; DENALI trial on track for data by YE2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and marketable securities $280.7M as of Sep 30, 2025; runway into late 2027.","R&D expenses $23.0M in Q3 2025, down 37.5% from $36.8M in Q3 2024.","G&A expenses $10.8M, down 26% from $14.6M YoY.","Phase 2 DENALI trial of azenosertib in Cyclin E1-positive PROC on track; topline data expected by year end 2026, potentially supporting accelerated approval.","TETON Phase 2 in USC completed enrollment; further development limited to partnering or capital allocation."],"consensus_eps_estimate":-0.5384,"consensus_eps_actual":-1.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140838,"accession_number":"0001725160-25-000154","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2025-08-26T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Zentalis appoints James B. Bucher as Chief Legal Officer; Andrea Paul resigns to join law firm","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrea Paul resigns as Chief Legal Officer and Corporate Secretary effective Sept 18, 2025.","James B. Bucher appointed as new Chief Legal Officer and Corporate Secretary effective same date.","Paul will remain a non-executive employee through Oct 1, 2025, and expects release agreement including 2025 bonus and equity vesting.","Bucher previously led legal at Harpoon Therapeutics during its Merck acquisition and at Alder Biopharmaceuticals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140837,"accession_number":"0001725160-25-000147","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Zentalis reports Q2 2025 cash of $303.4M; DENALI Phase 2 on track for topline by end 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities $303.4M as of June 30, 2025; runway extended into late 2027.","R&D expenses fell to $27.6M from $48.4M YoY; G&A expenses fell to $8.4M from $16.7M YoY.","DENALI Phase 2 trial of azenosertib in Cyclin E1-positive PROC remains on track; topline data expected by year-end 2026.","Strategic restructuring completed; no further non-recurring expenses expected.","Part 2 data, if successful, could support accelerated approval subject to FDA feedback."],"consensus_eps_estimate":-0.593,"consensus_eps_actual":-1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158588,"accession_number":"0001725160-25-000127","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Zentalis shareholders elect three directors, approve auditor and say-on-pay at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Scott Myers (43.0M for), Karan Takhar (30.7M for), and Luke Walker (36.6M for) elected as Class II directors.","Ratification of Ernst & Young as auditor approved with 58.1M votes for (over 99.9% of votes cast).","Advisory say-on-pay passed with 29.5M for vs 17.4M against (~63% of votes cast excluding broker non-votes).","Total 58.2M shares voted (80.9% of outstanding common stock as of April 21, 2025 record date)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158587,"accession_number":"0001725160-25-000119","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zentalis reports azenosertib triplet achieves 35% ORR and 5.8-month PFS in BRAFi-naïve mCRC at ASCO 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORR of 35.3% (12/34 confirmed responses) in BRAF inhibitor-naïve patients; median DoR 6.0 months (95% CI 4.4-NE).","Median PFS of 5.8 months (95% CI 3.9-9.2) in BRAF-naïve subset; prior BRAFi-treated patients had 1.8 months.","MTD set at azenosertib 300 mg + encorafenib 75 mg + cetuximab 500 mg/m2; no DLTs at MTD, manageable safety.","Most common TRAEs were asthenia (36%) and decreased appetite (34%); grade 3/4 asthenia occurred in 11% across all doses.","Efficacy exceeded historical encorafenib + cetuximab doublet (BEACON: ORR 20%, PFS 4.2 months) in BRAF-naïve mCRC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158586,"accession_number":"0001725160-25-000108","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zentalis to present at three investor conferences in May-June 2025","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["H.C. Wainwright BioConnect Conference – May 20, 2025, at 11:30 a.m. ET in New York, NY.","TD Cowen Oncology Innovation Summit – May 27, 2025, at 11:00 a.m. ET (virtual).","Jefferies Healthcare Conference – June 4, 2025, at 9:55 a.m. ET in New York, NY."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158585,"accession_number":"0001725160-25-000104","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zentalis Q1 2025 cash $332.5M; first patient dosed in DENALI Part 2 azenosertib trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $332.5M (incl. $12.2M Immunome stock) at March 31, 2025; runway into late 2027.","First patient dosed in DENALI Part 2a for azenosertib in Cyclin E1+ platinum-resistant ovarian cancer.","Topline data from DENALI Part 2 expected by year-end 2026; potential for accelerated approval.","R&D expenses $27.2M vs $49.6M YoY; total operating expenses $45.6M including $7.8M restructuring.","Prior Part 1b data: ORR 34.9%, median DOR 6.3 months in evaluable Cyclin E1+ PROC patients."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158584,"accession_number":"0001725160-25-000082","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Azenosertib shows RB1 loss sensitivity in SCLC/TNBC; cfDNA MR predicts HGSOC response","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preclinical: RB1 loss sensitizes TP53-mutant SCLC/TNBC cells; in vivo TGI 90% in RB1-mutant vs 49% in WT xenografts (Ex-99.1).","Clinical (N=123 HGSOC): cfDNA TP53 molecular response (MR) predicts RECIST response; MR+ median TTP 5.49 vs 2.69 months for MR- (HR 0.43, p<0.0001).","Complete MR (mCR) yields 6.5-month median TTP; MR precedes RECIST by 14 weeks for responders and 8 weeks for progressors (Ex-99.2).","Azenosertib shows synergistic activity with encorafenib + cetuximab in BRAF V600E preclinical models (Ex-99.4)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176982,"accession_number":"0001725160-25-000070","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zentalis FY2024 cash $371.1M; azenosertib 34.9% ORR in PROC; cash runway to late 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $371.1M; projected runway to late 2027. FY2024 op expenses $258.6M, down from $299.5M.","Azenosertib monotherapy 34.9% ORR (n=43) in Cyclin E1+ PROC from DENALI Part 1b; mDOR 6.3 months.","FDA Fast Track for azenosertib in PROC. DENALI Part 2 enrollment H1 2025, topline data by end 2026.","New CEO Julie Eastland, CMO Ingmar Bruns, and other executives appointed in Nov 2024.","Jan 2025 strategic restructuring to reduce costs; workforce reduction substantially complete Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176981,"accession_number":"0001628280-25-012899","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zentalis reports azenosertib ORR ~35% and mDOR 6.3 months in Cyclin E1+ PROC; Part 2 initiation on track for 1H2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Azenosertib demonstrated ORR of 34.9% (15/43) in response-evaluable Cyclin E1+ PROC patients; mDOR 6.3 months (95% CI: 2.7–NE) as of Jan 13, 2025 cutoff.","Cyclin E1 overexpression by IHC identified as predictive biomarker; ~50% of PROC patients overexpress Cyclin E1.","Safety profile consistent; most common TRAEs were GI toxicities and fatigue; 21.6% discontinued due to TRAEs.","Initiation of DENALI Part 2 in 1H 2025 on track; registration-intent topline data expected by year end 2026.","Preclinical data show synergistic antitumor effects of azenosertib combined with microtubule inhibitor-based ADCs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176980,"accession_number":"0001725160-25-000013","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Zentalis reports azenosertib ORR 34.9% in Cyclin E1+ PROC; FDA aligned on DENALI Part 2 for accelerated approval path","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DENALI Part 1b in Cyclin E1+ PROC achieved 34.9% ORR (response-evaluable n=43) and ~5.5 months median DOR; ITT ORR 31.3%.","FDA aligned on seamless DENALI Part 2 design; enrollment to begin 1H 2025 with topline data by year-end 2026; potential accelerated approval.","MAMMOTH monotherapy in Cyclin E1+ patients at 400mg QD 5:2 showed 31.3% ORR (n=16); safety profile well-characterized with low discontinuation rate.","Company discontinues ZN-c3-016 (BRAF CRC expansion) due to resource prioritization; no further development of niraparib combination.","Corporate restructuring extended cash runway into late 2027, beyond expected DENALI Part 2 data readout."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176979,"accession_number":"0001725160-25-000006","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["2.05","7.01","8.01","9.01"],"status":"ready","headline":"Zentalis restructures with 40% workforce cut, focuses WEE1 inhibitor, cash to late 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approves workforce reduction of approx. 40%; substantially complete by Q2 2025.","Expects $7.0-8.0M in one-time termination costs in Q1 2025.","Believes cash runway extended into late 2027, beyond potential azenosertib data readout.","Registration-enabling DENALI Part 2 data readout anticipated by end of 2026.","Corporate event on Jan 29, 2025, to present azenosertib clinical data and regulatory update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193765,"accession_number":"0001725160-24-000193","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K/A","filed_at":"2024-12-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Zentalis appoints Scott Myers to Compensation Committee; annual retainer $7,500","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Scott Myers appointed to Compensation Committee effective December 17, 2024.","Annual retainer of $7,500 for committee service under Non-Employee Director Compensation Program.","This amendment to the Nov 13, 2024 8-K adds the committee role and related compensation.","No other changes to the original 8-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193766,"accession_number":"0001725160-24-000177","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Zentalis appoints Julie Eastland CEO, succeeding Blackwell; plans registrational studies for azenosertib","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Julie Eastland appointed CEO, President and Director effective Nov 13, 2024; succeeds Kimberly Blackwell who resigned as CEO but remains strategic advisor.","Ingmar Bruns appointed Chief Medical Officer; Scott Myers appointed Board Chairperson.","Cam Gallagher resigned as President/Interim CFO; Vincent Vultaggio named interim principal financial officer.","Board approved amendment to 2022 Inducement Plan, increasing available shares by 5,500,000.","Company plans to host investor event in Jan 2025 with updated azenosertib data and regulatory update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210089,"accession_number":"0001725160-24-000161","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA lifts partial clinical hold on Zentalis' azenosertib studies; enrollment to resume","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared resumption of enrollment in all ongoing azenosertib studies with no changes to the clinical development plan.","Partial clinical hold was placed June 18, 2024; lifted after FDA review of comprehensive safety assessment.","Zentalis on track to present azenosertib monotherapy data and additional updates in Q4 2024.","CEO cites unwavering confidence in azenosertib's therapeutic index for gynecologic malignancies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210088,"accession_number":"0001725160-24-000157","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zentalis Q2 cash $426.4M; FDA partial hold on azenosertib; CMO resigns","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $426.4M as of June 30; R&D expense $48.4M (Q2 2024); cash runway into mid-2026.","FDA placed partial clinical hold on azenosertib June 18 after two deaths in DENALI study; resolution timelines uncertain.","Discontinued development of BCL-2 inhibitor ZN-d5; combination with azenosertib in AML phase 1 stopped.","CMO Diana Hausman stepped down effective Aug 8; CEO Kimberly Blackwell appointed Interim CMO; replacement search ongoing.","Expected 2H milestones: DENALI Cohort 1b topline, azenosertib Phase 1b final results, MAMMOTH data with GSK, others."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":40560000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228323,"accession_number":"0001725160-24-000140","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Zentalis shareholders elect Blackwell and Kariuki as directors; say-on-pay passes with 59% support","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Kimberly Blackwell received 48,055,584 votes for (78.9%) and Enoch Kariuki 45,008,378 for (73.9%) to Class I director seats.","Ratification of Ernst & Young as auditor for FY2024 passed nearly unanimously: 66,098,083 for, 5,665 against.","Advisory say-on-pay resolution approved with 36,128,130 for (59.3%) and 24,729,730 against (40.6%).","Total shares voted at annual meeting: 66,107,445, representing 93.09% of outstanding common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228322,"accession_number":"0001725160-24-000131","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zentalis files June 2024 corporate presentation; specific content not extractable from filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation furnished for use at investor conferences and meetings.","No financial or clinical updates disclosed in the filing text itself.","Exhibit 99.1 contains the full presentation but is not reproduced here."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228321,"accession_number":"0001725160-24-000120","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Zentalis appoints Luke Walker, M.D. to board, expanding to 7 directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 6 to 7 members; Dr. Walker appointed as Class II director effective May 24, 2024.","Term runs until 2025 annual meeting; Dr. Walker also joins Audit Committee.","Initial RSU grant of 72,481 shares valued at $850,000, vesting over 3 years.","Annual retainer for board service $45,000 plus $10,000 for Audit Committee membership.","Standard indemnification agreement signed; annual equity grants after 6 months service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228320,"accession_number":"0001725160-24-000106","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zentalis Q1 cash $489M; multiple azenosertib data readouts H2 2024–2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents & marketable securities $489.0M (incl $56.7M Immunome stock); projected runway to mid-2026.","R&D expense $49.6M (up $1M YoY); G&A $15.7M (down $0.7M). Quarterly net loss not disclosed.","Key milestones: Phase 1 osteosarcoma data at 2024 ASCO; DENALI (PROC) topline H1 2025; TETON (USC) topline H2 2025.","Interim CFO Cam Gallagher appointed April 5, 2024; search for permanent CFO underway.","Azenosertib development on track with partnerships (GSK, Pfizer); registration-enabling trial in PSOC planned for 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":40560000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228319,"accession_number":"0001725160-24-000087","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2024-04-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Melissa Epperly resigns; President Cam Gallagher named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Melissa Epperly resigned as CFO, treasurer, principal financial and accounting officer effective April 5, 2024.","President Cam Gallagher appointed interim CFO, treasurer and principal financial officer; VP Finance Vincent Vultaggio named interim principal accounting officer.","Chief Business Officer Kyle Rasbach will oversee Investor Relations on an interim basis.","Company is conducting a search for a new permanent CFO.","Epperly eligible for severance benefits under her amended employment agreement, subject to execution of a release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228318,"accession_number":"0001725160-24-000082","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zentalis presents corporate deck at conferences; no new financial or clinical updates disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Spokespersons to present the April 2024 corporate presentation at investor meetings and conferences.","Presentation furnished as Exhibit 99.1; no specific material changes or new data provided.","Filing under Regulation FD; information is furnished not filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247049,"accession_number":"0001725160-24-000079","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zentalis reports FY2023 cash $483M, azenosertib ORR 37%, appoints CMO/CBO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and securities $482.9M at Dec 31, 2023; runway into 2026; plus $35M upfront from Immunome in Jan 2024.","R&D expenses $189.6M (up 9.8%), G&A $64.4M (up 18%) versus FY2022.","Azenosertib Phase 1 monotherapy showed 37% ORR and 6.5-month mPFS in platinum-resistant ovarian/USC cancer patients.","Appointed Diana Hausman, M.D., as CMO and Kyle Rasbach, Ph.D., Pharm.D., as CBO.","NDA submission for azenosertib in gynecologic malignancy targeted for 2026; multiple data readouts in 2024-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247048,"accession_number":"0001725160-24-000057","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Zentalis adopts amended bylaws with universal proxy rule compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved Amended and Restated Bylaws effective February 12, 2024.","Amendments address SEC universal proxy rules under Rule 14a-19, including notice and solicitation requirements.","Enhanced disclosure requirements for stockholder director nominations and other business proposals.","Prohibits proposing more nominees than directors up for election.","Includes technical, modernizing, clarifying, and conforming changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247047,"accession_number":"0001725160-24-000012","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2024-01-25T23:59:59+00:00","items":["3.01","5.02","7.01","9.01"],"status":"ready","headline":"Zentalis appoints Diana Hausman as CMO, Kyle Rasbach as CBO; receives Nasdaq notice on audit committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Diana Hausman appointed CMO effective Jan 19, 2024; succeeds Carrie Brownstein who stepped down for personal reasons.","Kyle Rasbach appointed CBO; formerly portfolio manager at Eventide Asset Management.","Dr. Hausman resigned from Board and Audit Committee, causing Nasdaq audit committee independence non-compliance.","Company has 180 days (by July 17, 2024) to appoint a third independent director to regain compliance.","Dr. Brownstein receives severance: 10 months base salary + 2023 & prorated 2024 target bonuses, 12 months COBRA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247046,"accession_number":"0001725160-24-000007","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Zentalis licenses ROR1 ADC ZPC-21 to Immunome for $35M upfront, up to $275M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Exclusive worldwide license of preclinical ROR1 ADC ZPC-21 and proprietary ADC platform to Immunome.","Zentalis receives $35M upfront in cash and Immunome common stock; eligible for up to $275M milestones plus mid-to-high single-digit royalties.","Immunome plans to submit IND for ZPC-21 in 1Q 2025.","Zentalis to focus resources on advancing azenosertib (WEE1 inhibitor) in multiple clinical studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264485,"accession_number":"0001725160-23-000195","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Zentalis Q3: azenosertib 37% ORR, $517M cash, NDA on track for 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Azenosertib monotherapy achieved 37% ORR and 6.5-month mPFS in heavily pretreated ovarian/uterine serous carcinoma.","Cash, equivalents & marketable securities of $516.6M as of Sept 30, 2023; projected runway into 2026.","First NDA for azenosertib targeted in 2026 for a gynecologic malignancy; numerous trials ongoing.","Mark Lackner, Ph.D., to succeed co-founder Kevin Bunker, Ph.D., as Chief Scientific Officer at year-end.","ZN-d5 development in AL amyloidosis discontinued to focus resources on azenosertib franchise."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264484,"accession_number":"0001725160-23-000178","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2023-10-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Zentalis Pharmaceuticals COO Iris Roth departs effective Oct 10, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Iris Roth ceases as COO at 11:59 p.m. ET on Oct 10, 2023.","Company expects to provide severance benefits per Employment Agreement dated Feb 8, 2023.","No replacement or additional details on departure reason provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281718,"accession_number":"0001725160-23-000161","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2023-09-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zentalis Pharmaceuticals furnishes corporate presentation; no specific new data disclosed in excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated September 2023 will be used in investor meetings and conferences.","No financial results, pipeline updates, or guidance changes are available from the provided exhibit excerpt.","Filing under Regulation FD; information is furnished, not filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281717,"accession_number":"0001725160-23-000157","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zentalis Pharmaceuticals furnishes August 2023 corporate presentation; no material new data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["No earnings, guidance, or clinical data included in the 8-K filing.","Corporate presentation dated August 2023; content not fully provided here.","No changes to executive leadership, capital structure, or business strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281716,"accession_number":"0001725160-23-000154","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zentalis Q2 cash $553M; azenosertib ORR 36.8% with RP2D set","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $553.0M as of June 30, 2023; runway into 2026.","Azenosertib monotherapy ORR 36.8% in ovarian cancer/USC; RP2D set at 400 mg QD 5:2.","Phase 1b azenosertib + paclitaxel ORR 50.0% (mPFS 7.4 mo); + carboplatin ORR 35.7% (mPFS 10.4 mo).","Q2 R&D expense $42.7M, G&A $15.7M; one-time Zentera termination charge $45.6M.","Closed $250M public offering (11.03M shares at $22.66) in June; appointed CSO Kimberly Freeman."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300675,"accession_number":"0001725160-23-000148","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Zentalis shareholders reject advisory say-on-pay vote at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Advisory vote on executive compensation failed: 18.7M for, 34.3M against, 14K abstain.","Amendment to certificate of incorporation updating officer exculpation provision approved (48.5M for).","David Johnson and Jan Skvarka, Ph.D. elected as Class III directors with 38.6M and 52.5M votes for, respectively.","Ratification of Ernst & Young as auditor approved with 55.7M votes for.","93.81% of outstanding shares represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300674,"accession_number":"0001725160-23-000137","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Zentalis regains global rights to azenosertib, ZN-d5, ZN-c5 from Zentera","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated collaboration with Zentera Therapeutics; now holds worldwide development/commercialization rights to three drug candidates.","Pays $30M upfront, milestone payment, and low single-digit royalty on Greater China net sales of azenosertib, ZN-d5, ZN-c5.","Sold its 40.3% equity stake in Zentera back to Zentera for de minimis consideration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300673,"accession_number":"0001628280-23-022240","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Zentalis prices public offering of 11M shares at $22.66, raising ~$235.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sale of 11,032,656 common shares at $22.66 per share; net proceeds estimated at $235.5M.","Net proceeds to be used for ongoing and planned clinical trials and working capital.","Closing expected on June 20, 2023, subject to customary conditions.","Underwriters include Morgan Stanley, Jefferies, and SVB Securities.","Offering conducted under effective shelf registration statement on Form S-3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300672,"accession_number":"0001725160-23-000131","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2023-06-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Zentalis announces azenosertib monotherapy RP2D with 36.8% ORR in ovarian/USC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RP2D set at 400 mg QD on 5:2 schedule; steady-state exposure more than doubled vs continuous dosing.","Confirmed ORR 36.8% (7/19) in ovarian/USC with intermittent dosing vs 19.2% (5/26) continuous.","No discontinuations due to TRAEs in intermittent cohorts; improved tolerability over continuous dosing.","Three Phase 2 monotherapy trials enrolling: Cyclin E1+ ovarian, USC, PARPi-resistant ovarian cancer.","Company plans H2 2023 update on Phase 1 dose optimization data and Phase 2 program timelines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300671,"accession_number":"0001725160-23-000129","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2023-06-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Zentalis presents ASCO data: azenosertib+chemo response linked to Cyclin E1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Azenosertib + chemo (paclitaxel, carboplatin, gemcitabine, PLD) shows ORR of 34% across 94 evaluable patients.","Cyclin E1 IHC+ patients had median PFS 9.86 mo vs 3.25 mo for low (HR 0.37, p=0.0078).","RP2D set: azenosertib 300 mg QD 5:2 + paclitaxel 80 mg/m2; RP2D with carboplatin 200 mg QD 5:2.","Phase 3 design proposed comparing azenosertib+chemo vs carboplatin doublet in Cyclin E1+ platinum-sensitive ovarian cancer.","ZN-d5 (BCL-2) + azenosertib phase 1/2 in AML enrolling; no efficacy data yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300670,"accession_number":"0001725160-23-000119","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2023-05-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Zentalis announces positive Phase 1b data for azenosertib; plans Phase 3 trial in Cyclin E1+ ovarian cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Azenosertib + paclitaxel achieved 50% ORR (7.4 months mPFS) in platinum-resistant ovarian cancer.","Cyclin E1+ tumors showed 40% ORR vs 8.3% in Cyclin E1- (HR=0.37; p=0.0078).","Well tolerated; Grade ≥3 AEs: thrombocytopenia (27.5%), neutropenia (25.5%), anemia (15.7%), fatigue (9.8%).","Phase 3 study of azenosertib in combination with chemotherapy in Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300669,"accession_number":"0001725160-23-000112","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Zentalis reports $392M cash; on track for azenosertib monotherapy dose, ASCO data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and marketable securities of $392M as of March 31, 2023; runway into Q2 2025.","R&D expenses $48.6M (up $2.5M YoY); G&A expenses $16.4M (up $4.6M YoY), with lease impairment charges.","On track to disclose azenosertib monotherapy dose in 1H 2023; positive Phase 1b chemo combo data in ovarian cancer at ASCO June 5.","Appointed Diana Hausman, M.D. to Board of Directors; Funda Meric-Bernstam, M.D. to Scientific Advisory Board.","ZN-d5 interim data in AL amyloidosis expected 2H 2023; Phase 1/2 combo with azenosertib in AML preliminary data also 2H 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300668,"accession_number":"0001725160-23-000073","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2023-04-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Zentalis to present positive Phase 1b data for azenosertib in ovarian cancer at ASCO; announces diagnostic partnerships","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Positive clinical data from Phase 1b trial of azenosertib + chemo in platinum-resistant ovarian cancer to be presented at ASCO June 5, 2023.","Cyclin E1 expression shown as predictive marker for clinical benefit from azenosertib.","Collaborations with Foundation Medicine and Roche Diagnostics to develop companion diagnostics for azenosertib.","Azenosertib is potentially first-in-class Wee1 inhibitor being investigated in multiple trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300667,"accession_number":"0001725160-23-000063","cik":1725160,"company_name":"Zentalis Pharmaceuticals, Inc.","ticker":"ZNTL","form_type":"8-K","filed_at":"2023-04-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Zentalis reports preclinical data linking Cyclin E1 to azenosertib sensitivity; expects clinical data in H1 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preclinical data show azenosertib kills Cyclin E1-high tumor cells in vitro and inhibits patient-derived in vivo models.","Data presented at AACR 2023 suggest CCNE1 amplification/Cyclin E1 expression as potential predictive marker for patient enrichment.","Company now expects to share Phase 1b ovarian chemo combination clinical data in H1 2023, ahead of original guidance.","Collaboration with Dr. Gordon Mills of Oregon Health & Science University on Wee1 inhibition studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":252000000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-04-17T23:59:59+00:00|300667"}